# Tirzepatide: What the 2024-2025 Trials Actually Found

> Tirzepatide is an FDA-approved dual GIP and GLP-1 receptor agonist. This site walks through the SURMOUNT-5 head-to-head (2025), SURMOUNT-1, and the full peer-reviewed trial record — one step at a time.

Plain-English summaries of the SURMOUNT-5 head-to-head, the SURMOUNT-1 obesity programme, and the growing post-approval literature. Every quantitative claim is cited.

## Start here: what Tirzepatide is and what the trials found

Tirzepatide is an FDA-approved prescription medicine for type 2 diabetes (approved May 2022), chronic weight management (approved November 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid synthetic peptide — think of it as a small protein molecule — engineered to activate two gut-hormone receptors at once: the GIP receptor and the GLP-1 receptor (GIP and GLP-1 are hormones your intestine releases after you eat, and they signal the pancreas to release insulin in response to rising blood sugar). Activating both receptors in a single molecule is new — earlier approved drugs in this family only activated GLP-1. The biggest number from the recent trials: in SURMOUNT-5, a 2025 head-to-head randomised trial against another approved dual-class drug (also a once-weekly subcutaneous injection), participants on tirzepatide lost an average of -20.2% of their body weight over 72 weeks versus -13.7% with the comparator [5]. In SURMOUNT-1, -20.9% body weight change was measured at the highest dose versus -3.1% with placebo over 72 weeks in 2,539 adults with obesity [4]. These are study-measured figures from randomised controlled trials, cited and reported in the New England Journal of Medicine. This site walks through those trials step by step — what was measured, in whom, at what doses, and what the evidence gaps are. What people report — including the downsides and the safety signals every reader should know — is on the [Tirzepatide effects](/effects) page.

## Tirzepatide mechanism of action: the dual-receptor difference

To understand what makes tirzepatide structurally different from older approved drugs in this class, start with the two incretin hormones it mimics. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are both released by your gut after a meal. Both stimulate insulin secretion from the pancreas in a glucose-dependent way — meaning they only push insulin release when blood sugar is actually elevated, which is why this class of drug has a low hypoglycaemia risk on its own. GLP-1 also slows gastric emptying (the speed at which the stomach passes food into the small intestine) and acts on brain centres that regulate appetite and food intake. Tirzepatide activates both receptors through one molecule. In vitro signalling studies found it engages the GIP receptor to a greater degree than the GLP-1 receptor — making it an 'imbalanced' dual agonist — and shows biased signalling at the GLP-1 receptor that favours cAMP (a cellular messenger) over beta-arrestin (a pathway that leads to receptor internalisation and reduced sensitivity). The proposed consequence of that bias is a more sustained insulin response [2]. The practical outcome of engaging both pathways is larger reductions in blood sugar and body weight than a selective GLP-1 agonist alone, which is exactly what head-to-head trials measured [3]. Understanding this mechanism is the foundation for reading the SURMOUNT and SURPASS trial data.

## The 2024-2025 trial landscape: what is new

The recent-research lens is the core of this site, and three 2024-2025 studies are the most significant. First, SURMOUNT-5 (Aronne LJ et al., N Engl J Med 2025): the first direct head-to-head randomised trial comparing tirzepatide to another once-weekly injectable in adults with obesity but without type 2 diabetes. Result: -20.2% body weight change with tirzepatide versus -13.7% with the comparator, a 6.5-percentage-point treatment difference that was statistically highly significant (P < 0.001) [5]. Higher proportions of tirzepatide participants reached >=10%, >=15%, >=20%, and >=25% weight reduction thresholds. Second, a SURMOUNT-1 DXA substudy (Look M et al., Diabetes Obes Metab 2025): used dual-energy X-ray absorptiometry — a gold-standard scan that separates fat mass from lean mass — in a subset of 160 participants. Of the weight lost, approximately 75% was fat mass and approximately 25% was lean mass, a ratio consistent across most subgroups [10]. Third, a 2025 systematic review and network meta-analysis published in Nature Medicine (McGowan B et al.) that pooled 56 randomised controlled trials covering six drug classes and 60,307 patients, and found both semaglutide and tirzepatide achieved greater than 10% total body weight loss versus placebo, while tirzepatide was additionally associated with remission of obstructive sleep apnea and metabolic dysfunction-associated steatohepatitis [11]. The [Tirzepatide research](/research) page walks through the full mechanism and trial record in detail.

## What the tirzepatide literature shows — and what it does not

The evidence base for tirzepatide is unusually large for a drug this new. The phase 3 SURPASS programme in type 2 diabetes spans SURPASS-1 through SURPASS-6 and a cardiovascular outcomes trial; the SURMOUNT programme in obesity spans SURMOUNT-1, -2, -3, -4, and -5, plus dedicated trials in metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, and heart failure with preserved ejection fraction. Tens of thousands of randomised participants. That scale gives the safety and efficacy estimates unusual precision. What the literature does not show: tirzepatide is not approved for type 1 diabetes, and the clinical trials that built its approval record enrolled adults with type 2 diabetes or obesity — not people without those conditions. Weight loss after stopping treatment reverses substantially, as SURMOUNT-4 documented (participants who switched to placebo after an initial period on treatment regained meaningful weight, while those who continued lost further [14]). The gastrointestinal side-effect profile — nausea, vomiting, diarrhoea, constipation — is real, dose-related, and the primary driver of discontinuation across trials [6]. The [tirzepatide side effects](/side-effects) page covers all of this in detail.

---

Peer-reviewed trial findings on tirzepatide, walked through step by step — not a prescription, not a clinic, not a vendor.